Harmony Biosciences Holdings (HRMY) Debt to Equity (2019 - 2025)
Historic Debt to Equity for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $0.2.
- Harmony Biosciences Holdings' Debt to Equity fell 3414.2% to $0.2 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.2, marking a year-over-year decrease of 3414.2%. This contributed to the annual value of $0.27 for FY2024, which is 3438.69% down from last year.
- According to the latest figures from Q3 2025, Harmony Biosciences Holdings' Debt to Equity is $0.2, which was down 3414.2% from $0.22 recorded in Q2 2025.
- Over the past 5 years, Harmony Biosciences Holdings' Debt to Equity peaked at $1.81 during Q1 2021, and registered a low of $0.2 during Q3 2025.
- Its 5-year average for Debt to Equity is $0.63, with a median of $0.41 in 2023.
- In the last 5 years, Harmony Biosciences Holdings' Debt to Equity crashed by 5587.3% in 2022 and then crashed by 1229.97% in 2024.
- Harmony Biosciences Holdings' Debt to Equity (Quarter) stood at $1.03 in 2021, then tumbled by 53.78% to $0.48 in 2022, then decreased by 12.87% to $0.41 in 2023, then plummeted by 34.39% to $0.27 in 2024, then dropped by 25.81% to $0.2 in 2025.
- Its Debt to Equity was $0.2 in Q3 2025, compared to $0.22 in Q2 2025 and $0.24 in Q1 2025.